Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders

This study is currently recruiting participants.
Verified April 2013 by Indiana University
Sponsor:
Collaborators:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT00870727
First received: February 2, 2009
Last updated: April 16, 2013
Last verified: April 2013

February 2, 2009
April 16, 2013
February 2009
March 2014   (final data collection date for primary outcome measure)
  • Clinical Global Impression - Improvement [ Time Frame: At Baseline and Week 8 ] [ Designated as safety issue: No ]
  • Aberrant Behavior Checklist Irritability Scale [ Time Frame: At Baseline and Week 8 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00870727 on ClinicalTrials.gov Archive Site
The Aberrant Behavior Checklist Lethargy, Stereotypy, Hyperactivity and Inappropriate Speech Subscales [ Time Frame: At Baseline and Week 8 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders

The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment with individuals with Pervasive Developmental Disorder. This is a double-blind, placebo-controlled study of aripiprazole in the management of the maladaptive behaviors of Pervasive Developmental Disorder. The investigators hypothesize that aripiprazole will be more effective than placebo for reducing aggression,tantrum and self-injurious behavior in children with Pervasive Developmental Disorder.

Pervasive developmental disorders (PDD) are characterized by severe impairments in social interaction and communication in addition to restricted patterns of interests and activities. Research suggests that a dysregulation of the dopamine and serotonin systems contributes to these interfering behaviors in individuals with PDD. After benefits of typical neuroleptics were reported in subjects with PDD, research shifted to the atypical antipsychotic which have been shown to be better tolerated and effective in this population. However, the atypical antipsychotics have also been associated with adverse effects. Thus there remains a need for a novel pharmacotherapy that would be safe and effective for children and adolescents with PDD. The primary objectives of this study is to determine whether aripiprazole is effective and well tolerated for irritability in children and adolescents with PDD NOS during an 8-week acute phase and whether the effectiveness and tolerability of aripiprazole is maintained during a 16-week continuation phase.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Pervasive Developmental Disorder
Drug: aripiprazole
Minimum dose of 2mg per day to a maximum of 20 mg per day over the first 4 weeks of treatment.
Other Name: Abilify
  • Placebo Comparator: 1 Double-Blind
    Short term treatment where subjects will be randomized to either aripiprazole or placebo
    Intervention: Drug: aripiprazole
  • Active Comparator: 2 Open-label Phase
    Longer term treatment( 4 months) with Aripiprazole
    Intervention: Drug: aripiprazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
March 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female outpatients between the ages of 5 and 17 years and greater than or equal to 15kg body weight.
  • Diagnostic and Statistical Manual Fourth Edition, Text Revised (DSM-IV-TR) diagnosis of Pervasive Developmental Disorder Not Otherwise Specified (PDD NOS).
  • Psychotropic medication-free for at least 2 days prior to screening laboratory tests and electrocardiogram (ECG).
  • Significant irritability as determined by a Clinical Global Impression Severity of greater or equal to 4(Moderately ill)and a score of equal to or greater than 18 on the Aberrant Behavior Checklist Irritability Subscale.
  • Intelligence quotient (IQ) of equal to or greater than 50 based on the Wechsler Intelligence Scale for Children (WISC), 4th edition; Leiter International Test of Intelligence-Revised will be used if a child is nonverbal but thought to have an IQ greater than or equal to 50.

Exclusion Criteria:

  • DSM-IV-TR diagnosis other than PDD NOS (autism, Asperger's disorder, Rett's disorder, or childhood disintegrative disorder), schizophrenia, bipolar disorder or substance abuse within the last 6 months.
  • Comorbid disorder with possible association to autism (e.g., Fragile X Syndrome, Tuberous Sclerosis).
  • A significant medical condition such as heart, liver, renal, or pulmonary disease, or a seizure disorder, as determined by history, physical examination, or laboratory testing.
  • Subjects with an active seizure disorder (history of febrile seizures in early childhood will be considered.
  • Females with a positive urine pregnancy test.
  • Evidence of a prior adequate trial of aripiprazole (defined as equal to or greater than 2 weeks at equal to or greater than 5 mg per day. When there is not evidence of a prior adequate trial, subjects must be medication-free for a least 2 weeks prior to baseline.
  • History of neuroleptic malignant syndrome.
  • Subjects who, in the opinion of the investigator, are unsuitable in any other way to participate in this study, including being unable to comply with the requirements of the study for any reason.
  • Hypersensitivity to aripiprazole[e.g., allergic response or serious averse effect] (significant tachycardia)
Both
5 Years to 17 Years
No
Contact: Arlene Kohn 317-944-1990 aekohn@iupui.edu
United States
 
NCT00870727
0805-26, MH 082119
Yes
Indiana University
Indiana University
  • National Institute of Mental Health (NIMH)
  • Bristol-Myers Squibb
Principal Investigator: Kimberly A. Stigler, MD Indiana University School of Medicine
Indiana University
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP